Hope and Healing Cancer Services | Hinsdale, IL

Research site

(Unclaimed)

Location

950 North York Road Suite 201A, Hinsdale, Illinois, United States of America

Site insights

Top conditions

Top treatments

Bevacizumab

Pembrolizumab

Panitumumab

Telisotuzumab

Leucovorin

Trifluridine

Gemcitabine

relatlimab+nivolumab

Sacituzumab

5-FU

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

19 of 23 total trials

A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse even...

Enrolling

Metastatic Colorectal Cancer

Drug: ABBV-400

Drug: Trifluridine/Tipiracil

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (COPERNICUS)

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumo...

Enrolling

Carcinoma, Non-Small-Cell Lung

Drug: Chemotherapy: Carboplatin

Drug: Lazertinib

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to...

Enrolling

Endometrial Cancer

Metastatic Cancer

Drug: Gemcitabine

Drug: ART0380

A Study of REC-4881 in Participants with Cancers Which Have an AXIN1 or APC Mutation

This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatmen...

Active, not recruiting

Solid Tumor

APC Gene Mutation

Drug: REC-4881

A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy t...

Enrolling

Multiple Myeloma

Drug: ABBV-383

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (TAILOR)

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...

Enrolling

Small Lymphocytic Lymphoma

Leukemia, Lymphocytic, Chronic, B-Cell

Drug: Venetoclax

Drug: Ibrutinib

Locations recently updated

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC)

CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adve...

Enrolling

Metastatic Colorectal Cancer

Drug: Oxaliplatin

Drug: Panitumumab

Locations recently updated

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related d...

Enrolling

Non Small Cell Lung Carcinoma

Drug: Carboplatin

Drug: Pembrolizumab

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection comp...

Begins enrollment in 1 month

Metastatic Gastric Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma

Drug: 5-fluorouracil (5-FU)

Drug: Cisplatin

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer (VERITAC-2)

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Active, not recruiting

Advanced Breast Cancer

Drug: ARV-471

Drug: Fulvestrant

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also kn...

Enrolling

Melanoma

Drug: fianlimab

Drug: cemiplimab

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whethe...

Enrolling

Colorectal Cancer

Drug: Fruquintinib

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer (Amelia-1)

This is a Phase 1b/2, open-label, parallel-arms pilot study in men and post-menopausal women with hormone receptor positive (HR+), HER2- advanced or...

Enrolling

HR+/HER2-negative Breast Cancer

Metastatic Breast Cancer

Drug: Evexomostat

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

The goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, p...

Active, not recruiting

Colorectal Cancer (CRC)

Melanoma

Biological: GEN1042

Drug: Nab paclitaxel

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic in...

Active, not recruiting

Solid Tumor

Malignant Neoplasm

Drug: nab-sirolimus

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease (FourLight-3)

The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, rib...

Enrolling

Breast Cancer

Drug: PF-07220060

Drug: letrozole

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (EVOKE-SCLC-04)

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of ca...

Enrolling

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Drug: Topotecan

Drug: Sacituzumab Govitecan (SG)

Locations recently updated

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

The aim of this study is to compare progression free survival (PFS) in treatment-naïve Participants with KRAS p.G12C mutated metastatic colorectal ca...

Enrolling

Metastatic Colorectal Cancer

Drug: FOLFIRI Regimen

Drug: Bevacizumab-awwb

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. (Be6A Lung-02)

The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alon...

Enrolling

Carcinoma, Non-Small-Cell Lung (NSCLC)

Carcinoma, Non-Small-Cell Lung

Drug: Pembrolizumab

Drug: Sigvotatug Vedotin